Abstract: Psoriasis is a common chronic and disabling infl ammatory disease that has an enormous physical, functional and psychosocial impact on patients' quality of life. To date several conventional therapies are available for the treatment of this condition (eg, cyclosporine, methotrexate, retinoids, and psoralen plus ultraviolet A) which, although providing clinical response, do not maintain long-lasting disease remission and at times show poor tolerability with potential toxicity thus limiting their use. A challenge in psoriasis management is to utilize precociously an adequate therapy and to achieve effective and safe maintenance of its clearance by improving both skin and joint manifestations as well as to prevent joint destruction and disability. Recent improvement in the knowledge of the pathogenesis of this disease was fundamental for the development of novel targeted treatment options that may be effective, safer and well tolerated on long-term administration periods, thus improving patient's quality of life. These novel agents, which are called "biologics", target specifi cally tumor necrosis factor-α (infl iximab, etanercept and adalimumab) or T cells (alefacept and efalizumab).
Introduction
Psoriasis is a common, chronic, relapsing infl ammatory skin disease that can be associated with signifi cant morbidity. Patients affected by severe psoriasis constitute approximately 20%-30% of all patients with this disease and often require systemic treatment which has a major economic impact on the Health Service (Sampogna et al 2004; Stern et al 2004; Smith et al 2005) .
The aim of a chronic treatment is a balance between preventing disease-associated morbidity and disability, and minimizing side effects and organ toxicity consequent to prolonged use of a single agent. Standard systemic therapies available for the treatment of moderate-to-severe plaque psoriasis include photochemotherapy, retinoids, cyclosporine, methotrexate, and fumarates. Although many patients benefi t from many of these therapies and are able to achieve disease control, few are ever completely disease free and some are ineligible because of side effects or comorbidities. In addition, the unrestricted long-term administration is not recommended due to the potential cumulative toxicity and the possibility of treatment-resistance (Griffi ths et al de Rie et al 2004; Rapp and Feldman 2004; Stern et al 2004; Saraceno and Griffi ths 2006) .
Over the last 5-7 years, there has been a signifi cant advance in devising new drugs, the so-called biologics, which emerged as potentially alternative valuable therapeutic options for severe psoriasis and may be used safely over the long term with less toxicity than other traditional systemic treatments. The recent advances in the understanding of the immunopathogenesis of psoriasis and the identifi cation of key cytokines and immune cells, eg, tumor necrosis factor (TNF)-α and T-cells, revolutionized the management of this chronic disease. Biologics describe agents designed to block specifi c molecular steps important in the pathogenesis of psoriasis, and include two main groups: (i) agents targeting the cytokine TNF-α (eg, etanercept, infl iximab, adalimumab) and (ii) agents targeting T cells or antigen-presenting cells (eg, efalizumab, alefacept) (Rapp and Feldman 2004; Papp 2005a) .
Fundamental principles of the immunopathogenesis of psoriasis
Psoriasis is a complex disease that is recently considered an immune-mediated, organ-specifi c (skin, or skin and joints) inflammatory condition, in which intralesional T lymphocytes trigger primed basal stem keratinocytes to proliferate and perpetuate the disease process. Moreover, the complex interactions between susceptibility genes, immunologic effector mechanisms and environmental trigger factors (eg, infections, antigens, drugs, physical and/or emotional stress) elicit the disease process in the skin. Although epidermal hyperproliferation and terminal differentiation are the fundamental abnormalities in psoriatic skin, there is an immune-mediated infl ammatory process involving cytokines, chemokines, antigen-presenting cells (APCs), eg, Langherans cells, neutrophils and natural killer T cells, and mature skin-homing peripheral CD4
+ and CD8 + T lymphocytes (Krueger et al 1984; Bhalearao and Bowcock 1998; Gaspari 2006) . In fully developed psoriatic skin lesions, innate immune cells (eg, neutrophils, dendritic APCs and natural killer T cells), adaptive immune T cells, and an infl ammatory infi ltrate are found (Gaspari 2006) . Both CD4 + and CD8 + T lymphocytes are present, with the CD4 + T lymphocytes being present mostly in the dermis. There are two subsets of CD8 + T lymphocytes: an epidermal homing subset expressing CD103 (integrin α E) and a subset that remains in the dermis, which may be in transit to or from the epidermis. These mature peripheral T lymphocytes in psoriatic lesions are skin-homing activated memory cells CLA (cutaneous leukocyte antigen + ), HLA antigen-DR + , which express α/β TCR. The epidermal CD8 + T lymphocytes also express CD103 that allows them to interact with E-cadherin, facilitating their migration into the epidermis and their ability to bind to epidermal cells. Therefore, both CD4 + and CD8 , lymphocyte function-associated antigen-3, CD54) for which there are receptors on the surface of T lymphocytes, present the processed peptides to the T cells, and fi nally growth factor production by the activated T lymphocytes (Figures 1-2 ) (Bhalerao and Bowcock 1998; Austin et al 1999; Prinz 2003; Griffi ths 2003) . Moreover, in skin lesions and in blood there is a defi ciency of T-regulatory cell suppressor activity that may lead to unrestrained T cell proliferation and chronic overproduction of chemokines and Th1-derived cytokines, eg, interferon-γ, interleukin-2, TNF-α, etc. These proinfl ammatory cytokines and growth factors target epidermal keratinocytes to hyperproliferate, develop abnormal differentiation and become resistant to apoptotic signals. Furthermore, epidermal hyperproliferation is supported by neoangiogenesis which is also driven by T cell-derived growth factors and infl ammatory cytokines (Austin et al 1999; Prinz 2003; Banchereau et al 2004; Gaspari 2006) .
TNF-α appears to be a critical cytokine in the pathogenesis of T cell-mediated autoimmune diseases, including psoriasis, where it is demonstrated that it is crucial for keratinocyte hyperproliferation, endothelial cell regulation, and recruitment/effector function of memory T cells (Vassalli 1992; Ettehadi et al 1994; Kimber et al 2000) . Moreover, TNF-α levels are increased in psoriatic lesions, compared with those in uninvolved skin in psoriatic patients and in the healthy skin of nonpsoriatic individuals. Serum and lesional TNF levels decrease after effective psoriasis therapy correlating with clinical improvement in the disease. These observations suggested the use of anti-TNF-α agents with the intent to interfere with the proinfl ammatory effects of this cytokine. Therefore, several TNF-α antagonists have been successfully utilized for the treatment of severe psoriasis (Gordon and Ruderman 2006) .
Targeted treatment options
Advances in the knowledge of the major role of T cells in the pathogenesis of psoriasis and the understanding of chronic infl ammatory pathways has led to the development of several biologic agents that may target specifi c infl ammatory steps. Many accessory molecules involved in the so-called immunologic synapse, have been targeted by biologic therapies (alefacept and efalizumab) which showed a signifi cant effi cacy in psoriasis by interfering with the effector CD4 + and CD8 + T lymphocyte activation and secretion of the cytokines (eg, IFN-γ and TNF-α) found in psoriatic lesions. The fi rst agent approved to treat adult patients affected by moderate-to-severe plaque psoriasis was alefacept (Amevive ® , Biogen Idec Inc.) and it is currently registered for use in several countries, including United States (US) but not the European Union (EU). Efalizumab (Raptiva ® , Genetech, Inc.; Serono International S.A.) is also registered for the same indication in many countries, including US and EU (Ellis and Krueger 2001; Krueger et al 2002; Lebwhol et al 2003; Jullien et al 2004; Rapp and Feldman 2004; Leonardi et al 2005) .
Therapeutic targeting of TNF-α with biologic agents such as etanercept, infl iximab, and adalimumab has proven the important role of this infl ammation mediator in psoriasis. Etanercept (Enbrel 
T cell inhibitors Alefacept
Alefacept is a recombinant protein that binds to CD2 on memory-effector T lymphocytes, inhibiting their activation and reducing the number of these cells. It is a fusion protein composed of an LFA-3 protein and human IgG1 fragment crystallizable (Fc) domain. The drug is administered by intramuscular (IM) injection or intravenous (IV) infusion. Patients treated with alefacept have experienced a reduction in CD45RO + memory T cells, which correlates with the clinical improvement. To date, no clinically signifi cant signs of immunosuppression, opportunistic infections, or increase in malignancy have been observed (Ellis and Krueger 2001; Lebwhol et al 2003) .
Alefacept has been evaluated as a weekly 7.5 mg IV administration and as a weekly IM 15 mg injection however, only the IM dose is currently available. The effi cacy and safety of alefacept 15 mg, weekly administered for 12-weeks, were evaluated in a randomized, placebo-controlled, Phase III trial of adult patients with plaque psoriasis (body surface area >10%). Two weeks after the treatment phase was completed (study week-14), the Psoriasis Area and Severity Index (PASI) improved by at least 75% from baseline (PASI-75) in 21% of the 166 patients who received alefacept 15 mg per week, with 42% achieving at least a 50% improvement from baseline (PASI-50). This compares with rates of 5 and 18%, respectively, for patients randomized to placebo (n = 168; P < 0.001 for both comparisons). Alefacept therapy appeared to be well tolerated, even with long-term use (Lebwhol et al 2003) .
A multicentre (63 sites in Europe, US, and Canada), randomized, double-blind, placebo-controlled, parallel-group study, comparing 10 mg and 15 mg of alefacept and placebo administered IM once-weekly for 12-weeks, demonstrated that treatment with 15 mg of alefacept provided a higher PASI reduction from baseline with adverse events similar to that of placebo (Ortonne 2003) .
The primary concern with alefacept is T lymphocyte depletion. Patients with CD4 + T lymphocyte counts below normal should not initiate therapy with alefacept. It also recommended to monitor twice-weekly the T cells. Weekly monitoring of CD4 + T cells is also recommended in patients treated in the United States (Papp 2005a ).
Efalizumab
Efalizumab is a humanized monoclonal antibody against the CD11a molecule. CD11a and CD18 are subunits of leukocyte function-associated antigen 1 (LFA-1), a T cell surface molecule important in T cell activation, T cell migration into skin, and cytotoxic T cell function. This drug binds to CD11a on T cells blocking the interaction between LFA-1 and intercellular adhesion molecule 1 (ICAM-1), its partner molecule for adhesion. The blockade is reversible and does not deplete T cells. The currently available formulation of efalizumab is delivered as a once-weekly subcutaneous (SC) injection (Jullien et al 2004) .
Multiple Phase III clinical trials have demonstrated the effi cacy, safety, and health-related quality-of-life (HRQOL) benefi ts of 12-weeks of SC efalizumab therapy (1 mg/kg/week) in patients with moderate-to-severe chronic plaque psoriasis. A total of 556 adult psoriatic patients were randomized to receive efalizumab (n = 369) or placebo (n = 187) doubleblind for 12-weeks; all patients were then eligible to receive extended efalizumab open-label treatment for an additional 12-weeks. Efalizumab treatment showed a signifi cant effect relative to placebo after 12-weeks, and the extended treatment Efalizumab has shown good safety profi le and no opportunistic infections, no clinical signs of immunosuppression, hepatotoxicity or nephrotoxicity associated to its use. The Phase III trials showed no evidence of T cell depletion or increased risk of end-organ toxicity, malignancy, or infection. The most common adverse events associated with efalizumab administration are acute fl u-like symptoms (eg, headache, chills, fever, myalgia, vomiting, and nausea) observed primarily after the fi rst two doses. The incidence of acute adverse events in patients treated with efalizumab at the following doses is comparable to that observed in the placebo group. Worsening of psoriasis and psoriasis variants has been observed in 3% of efalizumab patients during therapy and in 14% of patients following abrupt discontinuation of efalizumab, respectively a generalized infl ammatory reaction and a rebound. Furthermore, new-onset or worsening arthritis has been infrequently reported during clinical trials (Leonardi et al 2003; Sterry et al 2004; Menter et al 2005a) .
While the 12-week, double-blind, placebo-controlled, fi rst-treatment (FT) CLEAR trial period demonstrated the effi cacy/safety of efalizumab in moderate-to-severe plaque psoriasis including refractory or contraindicated patients for other systemic treatments, a further study of Sterry and colleagues (2006) assessed the effi cacy/safety during an open-label extended 24-week continuous treatment. Among efalizumab-treated patients who had <75% PASI improvement at week-12 FT, extended treatment led to PASI75 in 26.6%; patients who had PASI Ն50 and Յ75 improvement at week-12 FT, extended treatment led to PASI75 in 47.5%; among patients achieving PASI75 at week-12 FT, median time of relapse was 58 days; and, re-treatment after relapse led to an improvement of mean PASI of 62.3% from study baseline. Safety results were consistent of other previous studies and effi cacy results demonstrate additional benefi t of continuing efalizumab (Sterry et al 2006) .
TNF-α inhibitors Infl iximab
Infl iximab is a chimeric monoclonal antibody that binds membrane-bound and soluble TNF-α. It was the fi rst blocker studied for the treatment of psoriasis, approved by the FDA to treat moderate-to-highly active rheumatoid arthritis in combination with methotrexate, moderate-to-highly active Crohn's disease, and both rheumatoid arthritis and Crohn's disease who have failed to respond to conventional therapies. This drug is administrated as IV infusion (Rapp and Feldman 2004; Papp 2005a) . Effi cacy of infl iximab has been demonstrated in psoriasis patients in randomized, placebo-controlled Phase II trials. Results of an international multicenter, randomized, placebo-controlled Phase III trial of adult patients with plaque psoriasis treated with infl iximab 5 mg/kg were recently reported. At week-10 of treatment, the PASI-75 response rate was 80.4% in the infl iximab-treated group and 2.6% in the placebo-treated group. Response was sustained through week-24. However, excluding patients who missed 2 infusions, the PASI-75 rate at week-50 was 70.5%. The moderate reduction in effi cacy may be due to the development of inhibitory antibodies in a percentage of the patients (Reich et al 2005a) . The safety profi le for infl iximab during this extended treatment Phase III trial appears to be comparable to those observed during earlier studies. The incidence of adverse events and serious adverse events in infl iximabtreated patients was slightly elevated through the first 24-weeks of treatment, and one patient who received infl iximab died of sepsis. Elevations in aminotransferases were also observed in some infl iximab-treated patients. In this trial, infection rates were comparable between the treated and placebo groups (Reich et al 2005a) .
The results of a Phase III, multicentre, double-blind clinical trial which included 378 psoriatic patients demonstrated the effectiveness of infl iximab 5 mg/kg in both induction and maintenance regimen. At week-10, 80% of patients treated with infl iximab achieved PASI75 and 57% PASI90, compared with 3% and 1% in the placebo group (p < 0.0001). At week-24, PASI75 and PASI90 were maintained (p < 0.0001). At week-50, 61% achieved PASI75 and 45% achieved PASI90 in the infl iximab group (Reich et al 2005b) .
In a randomized comparison of continuous (every-8-week) vs. intermittent (as-needed) infl iximab maintenance regimens for the treatment of moderate-to-severe psoriasis demonstrated that, through week-50, response was best in the continuous infl iximab therapy group (Menter et al 2007) .
It is also demonstrated that therapy with infl iximab at the dose of 5 mg/kg signifi cantly improves the signs and symptoms of arthritis, dactylitis and enthesitis in patients with active PsA that had been resistan to disease-modifying antirheumatic drugs (DMARDs). Results from the infl iximab multinational psoriatic arthritis controlled trial (IMPACT) showed that a continuous infliximab treatment led to sustained benefi t through 50-weeks with a favorable benefi tto-risk ratio (Antoni et al 2005) .
Infl iximab has been associated with several adverse events. Infusion reactions, reported in 19% of patients in clinical trials, usually consist of fever or chills, chest pain, hypotension, hypertension, and dyspnea. Neutralizing antibodies are formed, and patients can develop a serumsickness reaction days after administration of the drug. Multiple reports have indicated mild and serious infections during treatment with infl iximab, in particular reactivation of latent tuberculosis (TB). The available in vitro and epidemiologic evidence for the TNF inhibitors (infl iximab and etanercept) shows that the risk of development of active TB is higher with infl iximab. Furthermore, a decrease of TNF-α activity is demonstrated to be correlated with an increase of susceptibility to TB. The reason that only some patients succumb to rapidly disseminated infection is unknown, but may be related to the extent of TNF blockade in different individuals. This difference in inhibition may also explain why the incidence of TB seems to be increased with infl iximab in comparison with the other TNF inhibitors. However, it has not been observed an increased risk of serious infection in infl iximab-treated patients. One of the major concerns with the use of TNF inhibitors is the potential development of lymphomas. The majority of cases (81%) were non-Hodgkin's lymphomas. Induction of antinuclear antibodies and anti-DNA antibodies is observed in some patients treated with infl iximab and etanercept. Recently, the induction of true lupus erythematosus by TNF inhibitors has been observed (Reich et al 2005a) .
Etanercept
Etanercept is a TNF-α receptor recombinant fusion protein, comprising domains of the 75-kDa human TNF receptor and human IgG 1 , which competitively inhibits the interaction of this cytokine with cell-surface receptors and binds soluble TNF, preventing its mediated cellular responses and modulating the activity of other proinfl ammatory cytokines regulated by TNF. Etanercept is self-administered as SC injections once or twice-weekly (Rapp and Feldman 2004; Papp 2005a) .
The effi cacy and safety benefi ts of etanercept after 12 and 24-weeks of therapy in patients with moderate-to-severe chronic plaque psoriasis have been demonstrated in Phase III clinical trials.
In the EU the recommended dosage is 25 mg administered SC twice-weekly for up to 24-weeks, although dosing at 50 mg twice-weekly is also possible for the fi rst 12-weeks followed by a dose reduction to 25 mg twice-weekly. Moreover, on the basis of published clinical data, European guidelines indicate that nonresponders should discontinue etanercept Biological markers and target therapies in psoriasis after 12-weeks and that re-treatment is possible after discontinuation. In the US, the recommended dosing of etanercept is 50 mg twice-weekly for the fi rst 12-weeks of treatment followed by 50 mg etanercept once-weekly.
A double-blind, randomized, placebo-controlled Phase III clinical study demonstrated the safety and effi cacy of 12 and 24-weeks of etanercept treatment. Results showed that etanercept was well tolerated and the adverse events observed during the fi rst 12-week placebo-controlled period were mild-to-moderate and the etanercept and placebo groups showed no signifi cant differences (Leonardi et al 2003; Papp et al 2005b) .
Etanercept has been used safely over the past few years. Injection-site reactions are the main adverse events noted. There have been observations of demyelinating disorders such as multiple sclerosis, allergic reactions, and aplastic anemia. It possesses a good safety profi le in regard to the risk of malignancy and infection. There was no apparent temporal association between the onset of clinical TB and the introduction of etanercept therapy. TNF antagonists might induce new-onset heart failure or exacerbate existing disease (Rapp and Feldman 2004; Papp 2005a ).
The safety data from an integrated database of 1347 patients from 3 randomized, double-blind, placebo-controlled clinical trials were analyzed by Gottlieb and colleagues (2006) . Rates of adverse events in the fi rst 12-weeks of etanercept monotherapy in the 3 trials were similar among all active groups as well as each active group compared with the placebo group, and no dose-related toxicities were reported.
A recent randomized, open-label study evaluated the effectiveness and safety of continuous versus interrupted etanercept therapy. All patients received uninterrupted etanercept 50 mg twice weekly during the fi rst 12-weeks, followed by either continuous or interrupted 50 mg once weekly in the next 12-weeks. At week-12, comparable high proportions of responders were in the continuous (71.3%) and interrupted (72%) groups. At week-24, the proportion of responders was greater in the continuous group (71% vs 59.5% of the interrupted group; p < 0.0001). Both treatment groups were generally well tolerated (Moore et al 2007) .
Adalimumab
Adalimumab is a fully human anti-TNF-α monoclonal antibody administered as 40 mg subcutaneously once every other week. It has been approved by the FDA for the treatment of rheumatoid arthritis and currently being evaluated in Phase II and III clinical studies for the treatment of moderate-to-severe plaque psoriasis and PsA. These trials showed impressive PASI responses, with 53% of patients on 40 mg every other week and 80% of patients on 40 mg weekly achieving a 75% reduction in the PASI. Adverse events reported were similar to placebo, with headache, injection site pain, nausea, elevated tryglicerides, cough, sinus congestion, and fatigue. Adalimumab was found to be effective for psoriasis refractory to other treatments including infl iximab and etanercept (Backer 2004; Chen et al 2004; Rapp and Feldman 2004; Menter et al 2005b; Papp 2005a; Winterfi eld et al 2005) .
Results of a double-blind, randomized, placebo-controlled study showed that patients with moderate-to-severe active PsA and chronic plaque psoriasis treated with adalimumab signifi cantly improved joint and skin manifestations, inhibited structural changes on radiographs, lessened disability due to joint damage, and improved quality of life. At week-12, 58% of the adalimumab-treated patients achieved an ACR20 response, compared with 14% of the placebo-treated patients (P < 0.001). At week-24, similar ACR20 response rates were maintained. Among the 69 adalimumab-treated patients evaluated with the Psoriasis Area and Severity Index (PASI), 59% achieved a 75% PASI improvement response at 24-weeks, compared with 1% of the 69 placebo-treated patients evaluated (P < 0.001) (Mease et al 2005) .
Summary
Biologic agents appear to offer an effective and safe alternative to conventional systemic therapies and phototherapy for the treatment of moderate-to-severe psoriasis. To date, patients treated with infl iximab, etanercept, adalimumab, efalizumab, alefacept have achieved successful therapy of psoriasis without the organ toxicity seen with the long-term standard systemic treatments. However, these agents have potential limitations which include the expected high costs of treatment, lack of long-term follow-up, and the selected nature of the patient populations treated.
